key: cord-0690910-bw8x0swk
authors: He, Xi; Quan, Shuo; Xu, Min; Rodriguez, Silveria; Goh, Shih Lin; Wei, Jiajie; Fridman, Arthur; Koeplinger, Kenneth A.; Carroll, Steve S.; Grobler, Jay A.; Espeseth, Amy S.; Olsen, David B.; Hazuda, Daria J.; Wang, Dai
title: Generation of a SARS-CoV-2 Replicon as a Model System to Dissect Virus Replication and Antiviral Inhibition
date: 2020-12-13
journal: bioRxiv
DOI: 10.1101/2020.12.12.422532
sha: 101274a845ccfefc2b4af86d5aff4f0bf9c5c6c4
doc_id: 690910
cord_uid: bw8x0swk

SARS-CoV-2 research and antiviral discovery are hampered by the lack of a cell-based virus replication system that can be readily adopted without biosafety level 3 (BSL-3) restrictions. Here, the construction of a non-infectious SARS-CoV-2 reporter replicon and its application in deciphering viral replication mechanisms and evaluating SARS-CoV-2 inhibitors are presented. The replicon genome is replication competent but does not produce progeny virions. Its replication can be inhibited by RdRp mutations or by known SARS-CoV-2 antiviral compounds. Using this system, a high-throughput antiviral assay has also been developed. Significant differences in potencies of several SARS-CoV-2 inhibitors in different cell lines were observed, which highlights the challenges of discovering antivirals capable of inhibiting viral replication in vivo and the importance of testing compounds in multiple cell culture models. The generation of a SARS-CoV-2 replicon provides a powerful platform to expand the global research effort to combat COVID-19.

The current pandemic of coronavirus disease 2019 (COVID-19) caused by the newly emerged 55 coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to more 56 than 62 million infections and 1.46 million deaths as of 30 November 2020 (1). In response to this 57 public health emergency, an unprecedented swift and concerted effort has been launched globally 58 to identify safe and effective therapeutics and vaccines against the rapidly spreading virus. 59 Presently, about 2000 SARS-CoV-2 investigational programs and clinical trials have been 60 registered (2). However, most of the treatment trials to date have focused on repurposing a limited 61 number of existing antivirals approved for other indications, such as lopinavir/ritonavir, approved 62 for treatment of HIV infection, or remdesivir, originally developed for treatment of Ebolavirus 63 infection. Although compounds directly targeting SARS-CoV-2 are urgently needed, discovery 64 and development of such compounds typically requires a decade of dedicated effort. One of the 65 major bottlenecks is that the replication of the SARS-CoV-2 is yet fully understood, and assays 66 used to study viral genome replication and test SARS-CoV-2 compounds must be performed in 67 BSL-3 laboratories which are not readily available to most researchers. 68 To address the need for a broadly accessible and robust cell-based SARS-CoV-2 replication 69 platform, a SARS-CoV-2 replicon was constructed. In this replicon, the spike (S) protein open 70 reading frame (ORF) was deleted and replaced with a gene encoding a firefly luciferase (Luc) and 71 green fluorescence (GFP) fusion protein. The sequences of envelope (E), membrane (M) and their 72 intergenic region were also deleted and replaced with a neomycin-resistance gene (Neo). The 73 replicon maintained all the genes and genetic elements necessary for replicating the full-length 74 and subgenomic (sg) RNAs. As a result, the system can be used to study many aspects of virus 75 life cycle, such as genome replication, gene expression and virus-host interactions. Deletion of the Another advantage of the transient replicon system over traditional live virus-based models is that 79 the replicon RNA can be introduced to a variety of cell lines, allowing for assessment of viral 80 replication under more physiologically relevant conditions. SARS-CoV-2 preferentially targets 81 the respiratory tract, but may also spread to other organs and tissues such as heart, liver, brain, 82 and kidneys (3) . In infected tissues, the virus has been detected in multiple cell types (3, 4) . 83 However, in tissue culture very few cell lines are permissive to productive SARS-CoV-2 infection 84 (5). As a result, most SARS-CoV-2 replication analysis and compound testing so far have been 85 performed in Vero E6 cells which may not fully recapitulate the complexity of infections in vivo. 86 In addition, a high throughput antiviral assay has been developed using the described replicon 87 system. Under those assay conditions, the sensitivities of viral replication to SARS-CoV-2 88 inhibitors were found to be cell line dependent, suggesting antiviral compounds may have 89 different potencies against the virus infecting different cell types in vivo. Therefore, the replicon 90 system also provides a valuable tool to screen, test and optimize antiviral compounds and to 91 elucidate their mechanism of action. 

Construction and characterization of SARS-CoV-2 replicon 95 A bacterial artificial chromosome (BAC) system was employed to construct the SARS-CoV-2 96 replicon. As the full-length SARS-CoV-2 replicon is ~28k nt, its cDNA, together with the 97 flanking regions, was synthesized as five fragments with overlapping ~30 base pairs and 98 subsequently assembled into a BAC vector. The replicon was also linked to a T7 minimal 99 promoter upstream of the 5' untranslated region (UTR), and a cassette containing a 26 nucleotide poly(A), a hepatitis D virus ribozyme (Rbz) and a T7 terminator at the 3' end to yield precise viral 101 genome terminus (Fig.1A) . 102 To produce the replicon RNA, the BAC containing the replicon cDNA was linearized by 103 restriction enzyme digestion and then transcribed in vitro by T7 RNA polymerase as described in 104 the Materials and Methods. The 5' end of the synthesized RNA was capped by an anti-reverse cap 105 analog (ARCA). The replicon RNA was electroporated into indicated cell lines, and amplification 106 of the replicon RNA was quantified by the expression of GFP or luciferase reporter genes. A 107 similar in vitro transcription strategy has also been successfully used in the coronavirus reverse 108 genetics systems to rescue recombinant SARS-CoV-2 viruses (6-8). 109 The replication of in vitro transcribed RNA was initially examined in 293T cells. According to 110 the coronavirus replication model (9), the viral genome is copied by replication-transcription 111 complex, both continuously to produce minus-strand templates for genome RNA synthesis and 112 discontinuously to produce minus-strand templates for sg mRNA synthesis. These two types of 113 RNAs have also been reported recently in the SARS-CoV-2 infected cells (10). The structural 114 proteins such as S, E, M and N are encoded by sg mRNAs (Fig. 1A) . Therefore, GFP in the 115 replicon RNA transfected cells is also likely expressed by the sg mRNAs. To confirm the 116 synthesis of the Luc/GFP sg mRNAs, RT-PCR analysis was performed on the transcripts in the 117 electroporated cells. The forward primer was positioned in the leader sequence of 5' UTR, and the 118 reverse primer was situated in the Luc/GFP coding region (Fig.1A) . This resulted in a primer pair 119 only amplifying Luc/GFP sg mRNA. Consistent with the GFP expression, the Luc/GFP sg mRNA 120 was detected as early as 12 h post electroporation (Fig.1B) . The presence of the Luc/GFP sg 121 mRNA also indicated that the in vitro transcribed replicon RNA produces a functional replicase 122 complex.

In addition to 293T cells, other cell lines such as A549, Calu-1 and Huh-7.5 cells were also 124 demonstrated to support the replication of the SARS-CoV-2 replicon RNA, as evidenced by the 125 GFP reporter gene expression in those cells following electroporation with the replicon RNA 126 (Fig. 1C) . To Since the SARS-CoV-2 replicon RNA was introduced to the cells by electroporation, bypassing 171 the natural entry pathways of the virus, as expected, the SARS-CoV-2 entry inhibitors were 172 inactive in the replicon-based assay (Table 1) . Also, due to the deletion of the structural proteins, 173 S, E and M, this replicon assay is unlikely to be capable of identifying compounds that inhibit 174 SARS-CoV-2 assembly or release. (Table 1) . 183 GS-441524 was relatively weaker in inhibiting the replicon activity in most cell lines compared to 184 remdesivir. 185 The M pro inhibitors, GC376, PF-00835231 and Boceprevir, also exhibited notable antiviral 186 activities in different cell lines using the replicon-based assay. The sensitivity of the replicon to 187 these compounds was also cell line dependent. GC376 and its parent compound GC373 (14, 18) 188 were highly potent in 293T and Calu-1 cells, but only modestly active in A549 and Vero cells. In 189 contrast, the EC50 value of PF-00835231 ranged from 32 to 175 nM in Calu-1, A549, and Huh- transcription. However, the replicon cDNA itself produced background GFP and luciferase 234 signals, and the reporter activities were more variable from experiment to experiment. 235 We also attempted to establish a stable cell line that could maintain the replicon RNAs but to date 236 have been unsuccessful. SARS-CoV-2 replicon might be toxic to the cells or cleared by 237 intracellular innate immunity. Efforts to suppress or modify innate immunity to permit the 238 tolerance of SARS-CoV-2 replicon are currently on-going.

The utility of the replicon system for studying SARS-CoV-2 genome replication and gene 240 expression was demonstrated by the observations that the replicon is fully capable of producing 241 sg mRNAs as seen in virus infected cells (Fig. 1) (Fig. 1A) , named F1 to F5, with ~30 bps overlap were synthesized by Genewiz (South 1,2,4,5) . Finally, pSMART BAC F(1,2,4,5) digested with Aat II and Asc I, and F3 digested with Swa I were ligated together using Gibson Assembly Kit, resulting in the full-287 length non-infectious SARS-Cov-2 replicon construct pSMART BAC-T7-scv2-replicon. 288 RdRp mutant replicon construction 289 The RdRp mutations were made to the replicon by BAC recombineering (30) . An ampicillin 290 (Amp) cassette was introduced to the RdRp immediately downstream of D761 residue, followed 291 by Gibson assembly approach to replace the Amp cassette with the D760N and D761N mutations. Quantification and data analysis 371 All numerical data are presented as the mean ± SD (standard deviations). EC50 was determined 372 by non-linear 4-parameter curve fitting using ActivityBase. Data presented in Fig. 1 

Multiorgan and Renal Tropism of SARS-CoV-2

New understanding of the damage of SARS-CoV-2 infection outside the 389 respiratory system

Comparative tropism, replication kinetics, and 394 cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical 395 manifestations, transmissibility, and laboratory studies of COVID-19: an observational 396 study

SARS-CoV-2 Reverse Genetics Reveals a Variable 404

Infection Gradient in the Respiratory Tract

Rapid 409 reconstruction of SARS-CoV-2 using a synthetic genomics platform

An Infectious cDNA Clone of SARS-CoV-2

A contemporary view of coronavirus 416 transcription

The Architecture of 418 SARS-CoV-2 Transcriptome

Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA 421 polymerase from severe acute respiratory syndrome coronavirus 2 with high potency

Therapeutic 432 efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys

Compassionate Use of Remdesivir for Patients with Severe Covid-19

Broad-spectrum inhibitors against 3C-like 446 proteases of feline coronaviruses and feline caliciviruses

Discovery of M Protease Inhibitors 450 Encoded by SARS-CoV-2

A SARS-CoV-2 protein interaction map reveals 470 targets for drug repurposing

CoV-2 antiviral drugs through large-scale compound repurposing

Author Correction: Feline coronavirus drug inhibits the main protease of 482 SARS-CoV-2 and blocks virus replication

Both Boceprevir and GC376 efficaciously 485 inhibit SARS-CoV-2 by targeting its main protease

The Discovery and Development of Boceprevir: A Novel

First-generation Inhibitor of the Hepatitis C Virus NS3/4A Serine Protease

Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and

Expressing the SARS-CoV-2 RNA Polymerase in Mice

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus 498 (2019-nCoV) in vitro

Role of multiple drug resistance 500 protein 1 in neutral but not acidic glycosphingolipid biosynthesis

Reporter 503 Replicons for Antiviral Drug Discovery against Positive Single-Stranded RNA Viruses

Characterization 509 of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit 510 hepatitis C virus replication in vitro

Identification and 514 biological evaluation of a series of 1H-benzo[de]isoquinoline-1,3(2H)-diones as hepatitis 515 C virus NS5B polymerase inhibitors

Chemical 519 genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

Persistent replication of hepatitis C virus replicons expressing the beta-lactamase 523 reporter in subpopulations of highly permissive Huh7 cells

Construction of a severe 526 acute respiratory syndrome coronavirus infectious cDNA clone and a replicon to study 527 coronavirus RNA synthesis

Simple and 529 highly efficient BAC recombineering using galK selection